BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In response to risks associated with external delivery systems, an implantable IV infusion system was developed. A multicenter, prospective, single-arm, clinical trial (DelIVery for PAH) was conducted to evaluate this system for treprostinil in PAH. This analysis describes the findings related to the implant procedure. METHODS: Patients (N = 64) with PAH (World Health Organization group 1) receiving stable IV treprostinil were enrolled. Patients were transitioned to a temporary peripheral IV infusion catheter prior to the procedure. System implantation was performed at 10 centers under general anesthesia or deep IV sedation by clinicians from v...
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprosti...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often...
Objectives Parenteral prostanoids infused via external pumps are well-established pulmonary arterial...
BackgroundThe use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often l...
BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via t...
Abstract Background Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary art...
Background: The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, pros...
Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary...
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medici...
Steven C Pugliese,1 Todd M Bull1,2 1Division of Pulmonary Sciences and Critical Care Medicine, Depar...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
Background: Subcutaneous treprostinil has dose-dependent beneficial effects in patients with severe ...
Gérald Simonneau, MD; on behalf of the Treprostinil Study Group† Study objectives: To assess the ef...
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprosti...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often...
Objectives Parenteral prostanoids infused via external pumps are well-established pulmonary arterial...
BackgroundThe use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often l...
BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via t...
Abstract Background Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary art...
Background: The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, pros...
Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary...
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medici...
Steven C Pugliese,1 Todd M Bull1,2 1Division of Pulmonary Sciences and Critical Care Medicine, Depar...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
Background: Subcutaneous treprostinil has dose-dependent beneficial effects in patients with severe ...
Gérald Simonneau, MD; on behalf of the Treprostinil Study Group† Study objectives: To assess the ef...
STUDY OBJECTIVES: To assess the efficacy and safety of continuous subcutaneous infusion of treprosti...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...
Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hyperten...